Success Metrics

Clinical Success Rate
95.0%

Based on 38 completed trials

Completion Rate
95%(38/40)
Active Trials
0(0%)
Results Posted
16%(6 trials)
Terminated
2(5%)

Phase Distribution

Ph phase_1
15
38%
Ph phase_2
25
63%

Phase Distribution

15

Early Stage

25

Mid Stage

0

Late Stage

Phase Distribution40 total trials
Phase 1Safety & dosage
15(37.5%)
Phase 2Efficacy & side effects
25(62.5%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

95.0%

38 of 40 finished

Non-Completion Rate

5.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

40

all time

Status Distribution
Completed(38)
Terminated(2)

Detailed Status

Completed38
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
40
Active
0
Success Rate
95.0%
Most Advanced
Phase 2

Trials by Phase

Phase 115 (37.5%)
Phase 225 (62.5%)

Trials by Status

terminated25%
completed3895%

Recent Activity

0 active trials
Showing 5 of 40
terminatedphase_1

Safety of Bryostatin in Patients With MS

NCT06190912
completedphase_2

Bryostatin Treatment of Moderately Severe Alzheimer's Disease

NCT04538066
completedphase_2

Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer

NCT00031694
completedphase_2

Paclitaxel and Bryostatin 1 in Treating Patients With Metastatic Prostate Cancer

NCT00005028
completedphase_2

A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease

NCT02431468
View all 40 trials

Clinical Trials (40)

Showing 20 of 40 trialsScroll for more
NCT06190912Phase 1

Safety of Bryostatin in Patients With MS

Terminated
NCT04538066Phase 2

Bryostatin Treatment of Moderately Severe Alzheimer's Disease

Completed
NCT00031694Phase 2

Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer

Completed
NCT00005028Phase 2

Paclitaxel and Bryostatin 1 in Treating Patients With Metastatic Prostate Cancer

Completed
NCT02431468Phase 2

A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease

Completed
NCT02221947Phase 1

Study to Evaluate the Preliminary Safety, Efficacy, PK and PD of Bryostatin 1 in Patients With Alzheimer's Disease

Terminated
NCT00006022Phase 1

Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer

Completed
NCT00087425Phase 2

Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Completed
NCT00003993Phase 1

Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma

Completed
NCT00006389Phase 2

Bryostatin 1 and Cisplatin in Treating Patients With Metastatic or Unresectable Stomach Cancer

Completed
NCT00003174Phase 1

Bryostatin 1 Plus Cladribine in Treating Patients With Relapsed Chronic Lymphocytic Leukemia

Completed
NCT00004144Phase 1

Bryostatin 1 Plus Gemcitabine in Treating Patients With Advanced Cancer

Completed
NCT00003936Phase 2

Bryostatin 1 in Treating Patients With Recurrent or Refractory Hodgkin's Disease

Completed
NCT00006942Phase 2

Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Completed
NCT00003108Phase 1

Cisplatin Plus Bryostatin 1 in Treating Patients With Advanced Cancer

Completed
NCT00005965Phase 2

Bryostatin-1 Plus Cisplatin in Treating Patients With Recurrent or Advanced Cancer of the Cervix

Completed
NCT00005056Phase 2

Bryostatin 1 In Treating Patients With Progressive Kidney Cancer

Completed
NCT00004008Phase 2

Bryostatin 1 in Treating Patients With Ovarian Epithelial Cancer

Completed
NCT00003242Phase 1

Bryostatin 1 Plus Paclitaxel and Cisplatin in Treating Patients With Advanced Solid Tumors

Completed
NCT00003443Phase 2

Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer

Completed

Drug Details

Intervention Type
DRUG
Total Trials
40